Atlas Trials

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Clinical trial NCT06587451 · TERMINATED

Trial details

NCT number
NCT06587451
Sponsor
Sandoz
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Melanoma
Start date
2024-12-19
Primary completion
2026-01-23
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.